Ginseng Diminishes Lung Disease in Mice Immunized with Formalin-inactivated Respiratory Syncytial Virus After Challenge by Modulating Host Immune Responses

Overview

Journal J Interferon Cytokine Res

Publisher Mary Ann Liebert

Specialty Allergy & Immunology

Date 2014 Jul 23

PMID 25051168

Citations 12

Authors

Jong Seok Lee

Min Kyoung Cho

Hye Suk Hwang

Eun-Ju Ko

Yu-Na Lee

Young-Man Kwon

Min-Chul Kim

Ki-Hye Kim

Young-Tae Lee

Yu-Jin Jung

Sang-Moo Kang

Affiliations

Soon will be listed here.

Abstract

Formalin-inactivated respiratory syncytial virus (FI-RSV) immunization is known to cause severe pulmonary inflammatory disease after subsequent RSV infection. Ginseng has been used in humans for thousands of years due to its potential health benefits. We investigated whether ginseng would have immune modulating effects on RSV infection in mice previously immunized with FI-RSV. Oral administration of mice with ginseng increased IgG2a isotype antibody responses to FI-RSV immunization, indicating T-helper type 1 (Th1) immune responses. Ginseng-treated mice that were nonimmunized or previously immunized with FI-RSV showed improved protection against RSV challenge compared with control mice without ginseng treatment. Ginseng-mediated improved clinical outcomes after live RSV infection were evidenced by diminished weight losses, decreased interleukin-4 cytokine production but increased interferon-γ production, modulation of CD3 T-cell populations toward a Th1 response, and reduced inflammatory response. Ginseng-mediated protective host immune modulation against RSV pulmonary inflammation was observed in different strains of wild-type and mutant mice. These results indicate that ginseng can modulate host immune responses to FI-RSV immunization and RSV infection, resulting in protective effects against pulmonary inflammatory disease.

Citing Articles

Antiviral activities of ginseng and its potential and putative benefits against monkeypox virus: A mini review.

Das R, Ratan Z, Rahman M, Runa N, Mondal S, Konstantinov K J Ginseng Res. 2023; .

PMID: 37362081 PMC: 10065872. DOI: 10.1016/j.jgr.2023.03.002.

Antiviral Potential of the Genus : An updated review on their effects and underlying mechanism of action.

Zhang Y, Zhong X, Xi Z, Li Y, Xu H J Ginseng Res. 2023; 47(2):183-192.

PMID: 36926608 PMC: 10014226. DOI: 10.1016/j.jgr.2022.11.003.

Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.

Hioki K, Hayashi T, Natsume-Kitatani Y, Kobiyama K, Temizoz B, Negishi H Front Immunol. 2022; 13:847616.

PMID: 35663999 PMC: 9160479. DOI: 10.3389/fimmu.2022.847616.

Evaluation of botanicals as potential COVID-19 symptoms terminator.

Caliskan U, Mancak Karakus M World J Gastroenterol. 2021; 27(39):6551-6571.

PMID: 34754152 PMC: 8554406. DOI: 10.3748/wjg.v27.i39.6551.

Pharmacological Efficacy of Ginseng against Respiratory Tract Infections.

Alsayari A, Bin Muhsinah A, Almaghaslah D, Annadurai S, Wahab S Molecules. 2021; 26(13).

PMID: 34279434 PMC: 8271507. DOI: 10.3390/molecules26134095.

References

Boelen A, Andeweg A, Kwakkel J, LOKHORST W, Bestebroer T, Dormans J . Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine. 2000; 19(7-8):982-91. DOI: 10.1016/s0264-410x(00)00213-9. View

Castilow E, Legge K, Varga S . Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008; 181(10):6692-6. PMC: 2596668. DOI: 10.4049/jimmunol.181.10.6692. View

Castilow E, Meyerholz D, Varga S . IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008; 180(4):2376-84. DOI: 10.4049/jimmunol.180.4.2376. View

Quan F, Kim Y, Lee S, Yi H, Kang S, Bozja J . Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis. 2011; 204(7):987-95. PMC: 3164432. DOI: 10.1093/infdis/jir474. View

Lu J, Yao Q, Chen C . Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009; 7(3):293-302. PMC: 2928028. DOI: 10.2174/157016109788340767. View

Kapikian A, Mitchell R, Chanock R, Shvedoff R, Stewart C . An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969; 89(4):405-21. DOI: 10.1093/oxfordjournals.aje.a120954. View

FULGINITI V, Eller J, Sieber O, JOYNER J, Minamitani M, MEIKLEJOHN G . Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969; 89(4):435-48. DOI: 10.1093/oxfordjournals.aje.a120956. View

Jessen B, Faller S, Krempl C, Ehl S . Major histocompatibility complex-dependent cytotoxic T lymphocyte repertoire and functional avidity contribute to strain-specific disease susceptibility after murine respiratory syncytial virus infection. J Virol. 2011; 85(19):10135-43. PMC: 3196413. DOI: 10.1128/JVI.00816-11. View

Tang Y, Graham B . Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest. 1994; 94(5):1953-8. PMC: 294611. DOI: 10.1172/JCI117546. View

10.

Waris M, Tsou C, Erdman D, Day D, Anderson L . Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol. 1997; 71(9):6935-9. PMC: 191977. DOI: 10.1128/JVI.71.9.6935-6939.1997. View

11.

Shibata S . Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci. 2001; 16 Suppl:S28-37. PMC: 3202208. DOI: 10.3346/jkms.2001.16.S.S28. View

12.

Waris M, Tsou C, Erdman D, Zaki S, Anderson L . Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 1996; 70(5):2852-60. PMC: 190142. DOI: 10.1128/JVI.70.5.2852-2860.1996. View

13.

Girard M, Cherian T, Pervikov Y, Kieny M . A review of vaccine research and development: human acute respiratory infections. Vaccine. 2005; 23(50):5708-24. PMC: 7130922. DOI: 10.1016/j.vaccine.2005.07.046. View

14.

Prince G, Denamur F, Deschamps M, Garcon N, Prieels J, Slaoui M . Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine. 2001; 19(15-16):2048-54. DOI: 10.1016/s0264-410x(00)00417-5. View

15.

Graham B . Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Respir Crit Care Med. 1995; 152(4 Pt 2):S63-6. DOI: 10.1164/ajrccm/152.4_Pt_2.S63. View

16.

Kim C, Yi S, Cho I, Ku S . Red-koji fermented red ginseng ameliorates high fat diet-induced metabolic disorders in mice. Nutrients. 2013; 5(11):4316-32. PMC: 3847732. DOI: 10.3390/nu5114316. View

17.

Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A . Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012; 7(5):e36812. PMC: 3348902. DOI: 10.1371/journal.pone.0036812. View

18.

Quan F, Kim Y, Vunnava A, Yoo D, Song J, Prausnitz M . Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010; 84(15):7760-9. PMC: 2897640. DOI: 10.1128/JVI.01849-09. View

19.

Prince G, Curtis S, Yim K, Porter D . Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol. 2001; 82(Pt 12):2881-2888. DOI: 10.1099/0022-1317-82-12-2881. View

20.

Murawski M, McGinnes L, Finberg R, Kurt-Jones E, Massare M, Smith G . Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2009; 84(2):1110-23. PMC: 2798376. DOI: 10.1128/JVI.01709-09. View